XSHE
002332
Market cap1.28bUSD
Oct 09, Last price
8.76CNY
1D
1.39%
1Q
6.18%
Jan 2017
2.10%
IPO
6.96%
Name
Zhejiang Xianju Pharmaceutical Co Ltd
Chart & performance
P/E
19.27
P/S
2.31
EPS
0.45
Div yield, %
4.63%
Shrs. gr., 5y
—
Rev. gr., 5y
-1.33%
Revenues
3.76b
-6.04%
Net income
450m
+13.21%
CFO
247m
-37.92%
Dividend
Sep 16, 20260.1 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Xianju Pharmaceutical Co.,Ltd. is a global enterprise specializing in the production and distribution of steroidal and hormonal pharmaceutical products. Its offerings span active pharmaceutical ingredients (APIs), specifically steroid-based medications and both male and female hormones, alongside various chemical intermediates. The company also provides a comprehensive selection of finished dosage forms, including tablets, capsules, granules, soft capsules, powder inhalations, creams, gels, injections, and powder-for-injection preparations. Established in 1972, Zhejiang Xianju Pharmaceutical Co.,Ltd. operates from its headquarters in Xianju, China.
Key people
Yaohua Wang
Chief Financial Officer · since 2013
Carlo Cartasegna
Deputy General Manager · since 2017
Wenhui Zou
Deputy General Manager · since 2025
Wangwei Zhang
Deputy General Manager, Secretary of the Board, Director · since 2024
Weiwu Chen
Director · since 2010
Jing Dai
Staff Elected Director · since 2025
Danhui Guo
Director · since 2025
Weihua Jin
General Manager, Director · since 2025
Yusong Zhang
Chairman of the Board · since 2025
Guojun Zhang
Director · since 2007
Qi Fu
Independent Director · since 2025
Yunhong Hao
Independent Director · since 2016
Bin Liu
Independent Director · since 2022
Headquarters & legal address
浙江省仙居县仙药路1号
台州市, ZJ 100000
CN
台州市, ZJ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||